Syngene International
Stock Snapshot
Price Performance
Vista Outlook
Basis of our Recommendation
Syngene International is currently navigating a challenging transition year, marked by leadership changes and a strategic pivot towards high-value contract development and manufacturing services. Management has acknowledged a significant revenue impact from the loss of a major client, leading to a forecasted revenue decline in FY27. However, they remain optimistic about a recovery in the second half of the year, driven by investments in AI-enabled drug discovery and a focus on specialized modalities. Vista's financial outlook reflects this cautious optimism, with expectations of continued long-term growth despite near-term margin pressures. The company's strategic shift away from low-margin services is essential for capturing future growth, although execution risks remain. Industry dynamics, including increasing demand for diversification in pharmaceutical supply chains and improving pricing power for Indian CDMOs, support Syngene's long-term prospects. Over the next 12-24 months, key opportunities include leveraging its scientific capabilities and expanding into high-growth areas, while watchpoints include the time required to convert new business opportunities and potential regulatory challenges
Why We Like This Stock
- Management's focus on high-value CDMO services is expected to enhance long-term growth potential
- Investments in AI-enabled drug discovery and specialized modalities position Syngene favorably in a growing market
- The industry's shift towards integrated CDMO partners supports Syngene's strategic direction
Things To Watch Out For
- The loss of a major client has led to a significant revenue decline, impacting short-term performance
- Execution risks associated with new facilities and the ongoing business model realignment may hinder growth
- Regulatory complexities and macroeconomic conditions could delay recovery and client retention
Key Parameters
Financial Snapshot
View Technicals Analysis →| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 3,489 | 3,642 | 3,739 | 3,356 | 3,471 |
| Profit Before Tax (Cr.) | 635 | 631 | 488 | 354 | 401 |
| PBT Margin | 18.2% | 17.3% | 13.1% | 10.6% | 11.5% |
| Net Profit (Cr.) | 504 | 498 | 383 | 279 | 315 |
| Earnings Per Share | 12.5 | 12.3 | 9.5 | 6.9 | 7.8 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| Goldman Sachs | ▲ Buy | 450 | 01-Sep-2026 |
| Moneycontrol | ▲ Overweight | nan | 31-Jul-2026 |
| Macguire | ▲ Outperform | 735 | 30-Jul-2026 |
| Kotak Securities | ▲ Buy | 680 | 25-Jun-2026 |
| Jeffries | ▼ Underperform | 410 | 04-May-2026 |
Company Overview
Show Company Profile
Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States of America, Europe, and internationally. The company provides discovery chemistry services, such as synthetic and medicinal chemistry, library and peptide synthesis, biomolecular science, organic electronic materials, and computational and analytical chemistry; discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, in vivo pharmacology, toxicology, and biologicals; and chemical, formulation, analytical, and clinical development services. It provides lead generation, preclinical development, API, and drug product development services; and clinical trial management, pharmacokinetic analysis/bioanalytical studies, biometrics and clinical data management, central lab, regulatory, medical monitoring, pharmacovigilance, and medical writing services. In addition, the company offers chemistry, biology, safety assessment, computational, and data sciences for traditional small molecule therapeutics; biologics; and specialty modalities, such as peptides, oligonucleotides, antibody-drug conjugates, and targeted degradation/stabilization. It serves pharmaceutical, biotechnology, animal health, nutrition, consumer goods, agrochemical, performance and specialty materials, and other companies. The company has collaborations with Bristol-Myers Squibb, Baxter Inc., and Amgen Inc. The company was incorporated in 1993 and is headquartered in Bengaluru, India. Syngene International Limited is a subsidiary of Biocon Limited.